N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine CAS 152460-09-8 Imatinib Mesylate Intermediate High Purity

Short Description:

N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine 

CAS: 152460-09-8

Appearance: Yellow or Almost Yellow Powder

Purity: ≥98.0% (HPLC) 

Intermediate of Imatinib Mesylate (CAS: 220127-57-1) in the treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+CML)

High Quality, Commercial Production 

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
Synonyms Imatinib Mesylate Intermediate; 2-(2-Methyl-5-nitroanilino)-4-(3-pyridyl)pyrimidine
CAS Number 152460-09-8
CAT Number RF-PI228
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C16H13N5O2
Molecular Weight 307.31
Melting Point 188.0~193.0℃
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Yellow or Almost Yellow Powder
Purity ≥98.0% (HPLC)
Moisture (K.F) ≤0.50% 
Total Impurities ≤2.0%
Maximum Single Impurity ≤1.0%
Residue on ignition ≤0.50%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage Intermediate of Imatinib Mesylate (CAS: 220127-57-1)

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine (CAS: 152460-09-8) with high quality. It is an intermediate typically in the synthesis of Imatinib Mesylate (CAS: 220127-57-1).
Imatinib Mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produces the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib Mesylate binds up this crucial kinase, halting CML related growth. Imatinib Mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. Formulations containing Imatinib Mesylate have been used in the treatment of various cancers.

  • Write your message here and send it to us